New infusion strategy aims to keep CAR t cells fighting leukemia longer
NCT ID NCT03186118
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tests whether giving special immune cells called T-APCs after CAR T cell therapy can help the CAR T cells persist longer in the body and prevent leukemia from returning. It involves 30 children and young adults with relapsed or refractory CD19+ leukemia who have already achieved remission with CAR T cells. The main goals are to check safety and see if the approach is feasible.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- T-cell Antigen Presenting Cells expressing truncated CD19 (T-APCs)
- What this could lead to
- If it works, this could help CAR T cells stay active longer and reduce the chance of leukemia coming back after treatment.
- What could go wrong
- This is a very early, small pilot study (Phase 1) focused on safety and feasibility. It may not show clear benefit, and there are risks of side effects from the infusions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2017
- Expected to finish
-
Jul 2033
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
1 year to 30 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of recurrent or refractory CD19+ leukemia * Adequate performance status * Able to tolerate apheresis, including placement of temporary apheresis line if required * Adequate renal, liver, cardiac, and respiratory function * Adequate absolute lymphocyte count * HIV negative; Hepatitis B and C negative within 3 months prior to enrollment. Exclusion Criteria: * Evidence of active clinically significant CNS dysfunction * Evidence of active malignancy other than CD19+ malignancy * Evidence of active GVHD, or on immunosuppressive GVHD therapy within 4 weeks prior to enrollment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD 19+ acute leukemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.